Long-term data from a clinical study by pharmaceutical company Roche have shown a significant survival advantage in patients with early-stage breast cancer. As the company announced, the study named "Katherine" examined the effectiveness and safety of Kadcyla as an adjuvant therapy compared to Herceptin.

The results show a continuous superiority of Kadcyla as it reduced the risk of recurrence or death from any cause by 46 percent compared to Herceptin. After three years, an impressive 88.3 percent of the patients treated with Kadcyla had not experienced a breast cancer recurrence, compared to 77 percent of the patients treated with Herceptin.

Kadcyla is already approved in over 113 countries and is considered a standard therapy for patients with HER2-positive early breast cancer who still have an invasive residual tumor after preoperative treatment. This is a significant development, as early diagnosed breast cancer is still one of the most common types of cancer in women, and early use of effective therapies is crucial for survival chances.

The groundbreaking study "Katherine" is part of Roche's commitment to developing innovative treatment options for patients with breast cancer. As a leading company in oncology, Roche relies on research and development to offer new and improved therapies. These latest data confirm the effectiveness and long-term benefits of Kadcyla and once again underscore the importance of personalized treatment options for cancer patients.

These positive results come at a time when Roche is also making progress in other areas of oncology. In the field of immunotherapy, Roche is a pioneer and has received important approvals for its products in recent months. This proven commitment to researching and developing life-saving treatments makes Roche a leading company in the fight against cancer.

Overall, the positive long-term data from the "Katherine" study once again demonstrate Roche's comprehensive and steadfast commitment to the development of life-saving treatments for cancer patients. With continuous research and development, Roche will continue to provide effective therapies for better survival and improved quality of life for patients worldwide.